IMPROVED VIRUS SAFETY AND PURITY OF A CHROMATOGRAPHICALLY PRODUCED FACTOR-IX CONCENTRATE BY NANOFILTRATION

被引：31
|
作者：
HOFFER, L
SCHWINN, H
BIESERT, L
JOSIC, D
机构：
[1] OCTAPHARMA PHARMAZEUT PROD MBH,A-1100 VIENNA,AUSTRIA
[2] GEORG SPEYER HAUS,D-60596 FRANKFURT,GERMANY
来源：
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS | 1995年 / 669卷 / 02期
关键词：
D O I：
10.1016/0378-4347(95)00107-T
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
A virus removal system based on tangential flow filtration was introduced into a Factor IX production process. Beside the intended virus reduction potency of filter membranes, an additional purification effect could be achieved. This purification effect was evaluated in detail by means of sodium dodecyl sulphate-polyacrylamide gel electrophoresis and size-exclusion HPLC. High-molecular-mass impurities were retained by the membrane, thus increasing the specific activity of the product.
引用
收藏
页码：187 / 196
页数：10
相关论文
共 50 条
  • [21] A retrospective survey on the safety of Replenine®, a high-purity factor IX concentrate
    Gascoigne, EW
    Dash, CH
    Harman, C
    Wilmot, D
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2004, 13 (03) : 187 - 195
  • [22] PHARMACOKINETIC STUDIES ON A NEW PURIFIED FACTOR-IX CONCENTRATE
    THOMAS, DP
    HAEMOPHILIA, 1995, 1 : 23 - 25
  • [23] CHARACTERIZATION OF NANOTIV, A HIGHLY PURIFIED FACTOR-IX CONCENTRATE
    OSTLIN, A
    LOF, AL
    ERIKSSON, B
    MATTSON, C
    MOBERG, U
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 1283 - 1283
  • [24] A NEW PURIFIED FACTOR-IX CONCENTRATE (REPLENINE) - INTRODUCTION
    THOMAS, DP
    HAEMOPHILIA, 1995, 1 : 5 - 6
  • [25] SAFETY OF HIGH-DOSES OF A MONOCLONAL ANTIBODY-PURIFIED FACTOR-IX CONCENTRATE
    WARRIER, I
    KASPER, CK
    WHITE, GC
    SHAPIRO, AD
    BERGMAN, GE
    AMERICAN JOURNAL OF HEMATOLOGY, 1995, 49 (01) : 92 - 94
  • [26] PREVENTION OF SEVERE HEMOPHILIA B WITH A FACTOR-IX CONCENTRATE
    LUDWIG, E
    LECHNER, K
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1974, 99 (25) : 1355 - 1361
  • [27] NO ACTIVATION OF THE COMMON PATHWAY OF COAGULATION AFTER LARGE DOSES OF A HIGH-PURITY FACTOR-IX CONCENTRATE
    MANNUCCI, PM
    BAUER, KA
    GRINGERI, A
    BARZEGAR, S
    SANTAGOSTINO, E
    TRADATI, FC
    ROSENBERG, RD
    THROMBOSIS AND HAEMOSTASIS, 1991, 65 (06) : 824 - 824
  • [28] COMPARISON OF HIGH-PURITY FACTOR-IX CONCENTRATES AND A PROTHROMBIN COMPLEX CONCENTRATE IN A CANINE MODEL OF THROMBOGENICITY
    MACGREGOR, IR
    FERGUSON, JM
    MCLAUGHLIN, LF
    BURNOUF, T
    PROWSE, CV
    THROMBOSIS AND HAEMOSTASIS, 1991, 66 (05) : 609 - 613
  • [29] EXAMINING THE PURITY AND SPECIFIC ACTIVITY OF FACTOR-IX CONCENTRATES
    VYAZOVA, YP
    AZHIGIROVA, MA
    SHUVALOVA, AL
    KHAMETOVA, RN
    FETISOVA, LV
    MOISEEVA, VG
    ZEINALOV, AM
    KHIMIKO-FARMATSEVTICHESKII ZHURNAL, 1991, 25 (06): : 60 - 63
  • [30] Measurement of activated factor IX in a high purity factor IX concentrate (Replenine®)
    Moola, Z
    O'Hara, H
    Crombie, D
    Talbot, J
    Winkelman, L
    THROMBOSIS AND HAEMOSTASIS, 1999, : 92 - 92
12345